Evercore (EVR) Adds A Healthcare Banker, Is The 11% Discount Enough?

Evercore (EVR) is back in focus after the firm appointed Eric Rabinowitz as a senior managing director in its healthcare investment banking group, bringing more than two decades of sector focused M&A experience.

See our latest analysis for Evercore.

At a share price of $334.15, Evercore has seen its short term share price return drift lower, with the 7 day move down 6% and the 30 day return down 6.5%. Its 1 year total shareholder return of 15.4% and 3 year total shareholder return of about 2.6x suggest longer term momentum has remained stronger.

If this healthcare hire has caught your attention and you want to see where else capital is flowing in the sector, take a look at 40 healthcare AI stocks

After the recent pullback, Evercore trades about 14% below both its average analyst price target and one intrinsic value estimate. The key issue now is whether that valuation gap reflects opportunity or caution.

Most Popular Narrative: 10.8% Undervalued

Evercore's most followed valuation narrative pegs fair value at $374.60, which sits above the last close of $334.15 and frames the current discount.

The ongoing globalization of capital markets and an accelerating trend in cross-border M&A activity are providing an increasingly fertile environment for independent, conflict-free advisors like Evercore. The firm's continued expansion into key international markets, as evidenced by new offices and hiring in EMEA (France, Spain, Italy, Dubai, UK), is cited as positioning it to capture an increasing share of advisory fee pools and drive top-line revenue over the long term.

Read the complete narrative.

Want to know what is really behind that $374.60 fair value for Evercore? Revenue assumptions, margin expectations, and future earnings multiples all play a critical role. Curious which of those levers the narrative leans on most heavily, and how far they are pushed? The full story sits in the detailed narrative model, not in the headline discount.

Result: Fair Value of $374.60 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the Evercore story also hinges on risks, including rising fixed and compensation costs, as well as the possibility that M&A activity or integration of Robey Warshaw underwhelms.

Find out about the key risks to this Evercore narrative.

Another View on Evercore Using Market Ratios

While the narrative and fair value work point to Evercore trading below some intrinsic estimates, the market ratios tell a more mixed story. At a P/E of 17.3x, the stock sits well below the US Capital Markets industry average of 40.2x, yet above the peer average of 12.6x.

It also screens as expensive versus a fair ratio P/E of 14.7x. This suggests the current price already incorporates some optimism relative to what the regression implied ratio indicates. For investors, that gap can appear as potential upside if the higher multiple is sustained, or as valuation risk if sentiment moves closer to peers and the fair ratio.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Looking at Evercore's mix of potential rewards and flagged risks, this is a moment to move quickly, review the underlying data and form your own stance. You can start with 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Evercore?

If Evercore has sharpened your interest, do not stop here. Use fresh stock screens to spot other opportunities before the crowd moves on without you.

• Hunt for potential mispricings by checking companies that currently screen as attractively valued using the 46 high quality undervalued stocks.
• Strengthen your income watchlist by reviewing companies identified as yield focused opportunities in the 8 dividend fortresses.
• Prioritize resilience by reviewing companies highlighted for robust financial footing in the 80 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com